WHAT IS CLAIMED IS:

1. A method for the treatment of cancerous cell growth mediated by raf kinase comprising administering a compound of formula I

I

wherein B is a substituted or unsubstituted, up to tricyclic, aryl or heteroaryl moiety of up to 30 carbon atoms with at least one 5- or 6-member aromatic structure containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur, wherein if B is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of halogen, up to per-halosubstitution, and X_n, wherein n is 0-3 and each X is independently selected from the group consisting of –CN, $-CO_2R^5$, $-C(O)NR^5R^{5'}$, $-C(O)R^5$, $-NO_2$, $-OR^5$, $-SR^5$, $-NR^5R^{5'}$, $-NR^5C(O)OR^{5'}$, $-NR^5C(O)R^{5'}$, C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_1-C_{10} alkoxy, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, C_7-C_{24} alkaryl, C_3-C_{13} heteroaryl, C_4-C_{23} alkheteroaryl, substituted C_1-C_{10} alkyl, substituted C_2-C_{10} alkenyl, substituted C_1-C_{10} alkoxy, substituted C_3-C_{10} cycloalkyl, substituted C_4-C_{23} alkheteroaryl and -Y-Ar;

wherein if X is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of –CN, $-CO_2R^5$, $-C(O)R^5$, $-C(O)NR^5R^{5'}$, $-OR^5$, $-SR^5$, $-NR^5R^{5'}$, $-NO_2$, $-NR^5C(O)R^{5'}$, $-NR^5C(O)OR^{5'}$ and halogen up to per-halo substitution;

wherein R^5 and $R^{5'}$ are independently selected from H, C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, C_3-C_{13} heteroaryl, C_7-C_{24} alkaryl, C_4-C_{23} alkheteroaryl, up to per-halosubstituted C_1-C_{10} alkyl, up to per-halosubstituted C_2-C_{10}

alkenyl, up to per-halosubstituted C_3-C_{10} cycloalkyl, up to per-halosubstituted C_6-C_{14} aryl and up to per-halosubstituted C_3-C_{13} heteroaryl,

wherein Y is - O-, -S-, -N(R^5)-, -(CH_2)-$_m$, -C(O)-, -CH(OH)-, -(CH_2)$_m$O-, -NR^5C(O)NR^5 N$R^{5'}$-, -NR^5C(O)-, -C(O)NR^5-, -(CH_2)$_m$S-, -(CH_2)$_m$N(R^5)-, -O(CH_2)$_m$-, -CHX^a, -CX^a_2-, -S-(CH_2)$_m$- and -N(R^5)(CH_2)$_m$-,

m = 1-3, and X^a is halogen; and

Ar is a 5-10 member aromatic structure containing 0-4 members of the group consisting of nitrogen, oxygen and sulfur which is unsubstituted or substituted by halogen up to per-halosubstitution and optionally substituted by Z_{n1}, wherein n1 is 0 to 3 and each Z is independently selected from the group consisting of –CN, =O, -CO_2R^5, -C(O)N$R^5R^{5'}$, -C(O)- NR^5, -NO_2, -OR^5, - SR^5, -N$R^5R^{5'}$, -NR^5C(O)O$R^{5'}$, -C(O)R^5, -NR^5C(O)$R^{5'}$, -SO_2R^5, SO_2N$R^5R^{5'}$, C_1-C_{10} alkyl, C_1-C_{10} alkoxyl, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, C_3-C_{13} heteroaryl, C_7-C_{24} alkaryl, C_4-C_{23} alkheteroaryl, substituted C_1-C_{10} alkyl, substituted C_3-C_{10} cycloalkyl, substituted C_7-C_{24} alkaryl and substituted C_4-C_{23} alkheteroaryl; wherein if Z is a substituted-group, it is substituted by the one or more substituents independently selected from the group consisting of –CN, -CO_2R^5, -C(O)N$R^5R^{5'}$, =O, -OR^5, -SR^5, -NO_2, -N$R^5R^{5'}$, -NR^5C(O)$R^{5'}$, -NR^5C(O)O$R^{5'}$, C_1-C_{10} alkyl, C_1-C_{10} alkoxyl, C_3-C_{10} cycloalkyl, , C_3-C_{13} heteroaryl, C_6-C_{14} aryl, C_4-C_{24} alkheteroaryl and C_7-C_{24} alkaryl, and

A is a heteroaryl moiety selected from the group consisting of



wherein

R^1 is selected from the group consisting of halogen, C_3-C_{10} alkyl, C_3-C_{10} cycloalkyl, C_1-C_{13} heteroaryl, C_{6-14} aryl, C_{7-24} alkaryl, up to per-halosubstituted C_1-C_{10} alkyl, up to per-halosubstituted C_3-C_{10} cycloalkyl, up to per-halosubstituted C_1-C_{13} heteroaryl, up to per-halosubstituted C_{6-14} aryl, and up to per-halosubstituted C_{7-24} alkaryl;

R^2 is selected from the group consisting of H, $-C(O)R^4$, $-CO_2R^4$, $-C(O)NR^3R^{3'}$, C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, C_7-C_{24} alkaryl, C_4-C_{23} alkheteroaryl, substituted C_1-C_{10} alkyl, substituted C_3-C_{10} cycloalkyl, substituted C_7-C_{24} alkaryl and substituted C_4-C_{23} alkheteroaryl,

where R^2 is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of -CN, $-CO_2R^4$, $-C(O)-NR^3R^{3'}$, $-NO_2$, $-OR^4$, $-SR^4$, and halogen up to per-halosubstitution,

wherein R^3 and $R^{3'}$ are independently selected from the group consisting of H, $-OR^4$, $-SR^4$, $-NR^4R^{4'}$, $-C(O)R^4$, $-CO_2R^4$, $-C(O)NR^4R^{4'}$, C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, C_3-C_{13} heteroaryl, C_7-C_{24} alkaryl, C_4-C_{23} alkheteroaryl, up to per-halosubstituted C_1-C_{10} alkyl, up to per-halosubstituted C_3-C_{10} cycloalkyl, up to per-

halosubstituted C_6-C_{14} aryl and up to per-halosubstituted C_3-C_{13} heteroaryl; and

wherein R^4 and $R^{4'}$ are independently selected from the group consisting of H, C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, C_3-C_{13} heteroaryl; C_7-C_{24} alkaryl, C_4-C_{23} alkheteroaryl, up to per-halosubstituted C_1-C_{10} alkyl, up to per-halosubstituted C_3-C_{10} cycloalkyl, up to per-halosubstituted C_6-C_{14} aryl and up to per-halosubstituted C_3-C_{13} heteroaryl,

R^a is C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, up to per-halosubstituted C_1-C_{10} alkyl and up to per-halosubstituted C_3-C_{10} cycloalkyl; and

R^b is hydrogen or halogen,

R^c is hydrogen, halogen, C_1-C_{10} alkyl, up to per-halosubstituted C_1-C_{10} alkyl or combines with R^1 and the ring carbon atoms to which R^1 and R^c are bound to form a 5- or 6-membered cycloalkyl, aryl or hetaryl ring with 0-2 members selected from O, N and S;

subject to the proviso that where A is



B is not



wherein n = 2-4,

or



.

2. A method as in claim 1, wherein B is up to a tricyclic aromatic ring structure selected from the group consisting of






and

;

which is substituted or unsubstituted by halogen, up to per-halosubstitution, and wherein

n = 0-3 and

each X is independently selected from the group consisting of –CN, $-CO_2R^5$, $-C(O)NR^5R^{5'}$, $-C(O)R^5$, $-NO_2$, $-OR^5$, $-SR^5$, $-NR^5R^{5'}$, $-NR^5C(O)OR^{5'}$, $-NR^5C(O)R^{5'}$, C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_1-C_{10} alkoxy, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, C_7-C_{24} alkaryl, C_3-C_{13} heteroaryl, C_4-C_{23} alkheteroaryl, and substituted C_1-C_{10} alkyl, substituted C_2-C_{10} alkenyl, substituted C_1-C_{10} alkoxy, substituted C_3-C_{10} cycloalkyl, substituted C_4-C_{23} alkheteroaryl and -Y-Ar;

wherein if X is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of –CN, $-CO_2R^5$, $-C(O)R^5$, $-C(O)NR^5R^{5'}$, $-OR^5$, $-SR^5$, $-NR^5R^{5'}$, NO_2, $-NR^5C(O)R^{5'}$, $-NR^5C(O)OR^{5'}$ and halogen up to per-halosubstitution;

wherein R^5 and $R^{5'}$ are independently selected from H, C_1-C_{10} alkyl, C_2-C_{10} alkenyl, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, C_3-C_{13} heteroaryl, C_7-C_{24} alkaryl, C_4-C_{23} alkheteroaryl, up to per-halosubstituted C_1-C_{10} alkyl, up to per-halosubstituted C_2-C_{10}

alkenyl, up to per-halosubstituted C_3-C_{10} cycloalkyl, up to per-halosubstituted C_6-C_{14} aryl and up to per-halosubstituted C_3-C_{13} heteroaryl,

wherein Y is - O-, -S-, -N(R^5)-, -(CH_2)-$_m$, -C(O)-, -CH(OH)-, -(CH_2)$_m$O-, -NR^5C(O)NR^5 $NR^{5'}$-, -NR^5C(O)-, -C(O)NR^5-, -(CH_2)$_m$S-, -(CH_2)$_m$N(R^5)-, -O(CH_2)$_m$-, -CHX^a, -CX^a_2-, -S-(CH_2)$_m$- and -N(R^5)(CH_2)$_m$-,

m = 1-3, and X^a is halogen; and

Ar is a 5-10 member aromatic structure containing 0-2 members of the group consisting of nitrogen, oxygen and sulfur which is unsubstituted or substituted by halogen up to per-halosubstitution and optionally substituted by Z_{n1}, wherein nl is 0 to 3 and each Z is independently selected from the group consisting of –CN, =O, -CO_2R^5, -C(O)$NR^5R^{5'}$, -C(O)R^5, -NO_2, -OR^5, - SR^5, - $NR^5R^{5'}$, -NR^5C(O)$OR^{5'}$, -C(O)R^5, -NR^5C(O)$R^{5'}$, -SO_2R^5, -$SO_2R^5R^{5'}$, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, C_3-C_{13} heteroaryl, C_7-C_{24} alkaryl, C_4-C_{23} alkheteroaryl, substituted C_1-C_{10} alkyl, substituted C_3-C_{10} cycloalkyl, substituted C_7-C_{24} alkaryl and substituted C_4-C_{23} alkheteroaryl; wherein if Z is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of –CN, -CO_2R^5, -C(O)$NR^5R^{5'}$, -OR^5, -SR^5, -NO_2, -$NR^5R^{5'}$, =O, -NR^5C(O)$R^{5'}$, -NR^5C(O)$OR^{5'}$, C_1-C_{10} alkyl, C_1-C_{10} alkoxyl, C_3-C_{10} cycloalkyl, , C_3-C_{13} heteroaryl, C_6-C_{14} aryl, C_4-C_{24} alkheteroaryl and C_7-C_{24} alkaryl.

3. A method of claim 1, wherein B is



wherein

Y is selected from the group consisting of –O-, -S-, -CH_2-, -SCH_2-, -CH_2S-, -CH(OH)-, -C(O)-, -CX^a_2, -CX^aH-, -CH_2O- and -OCH_2-,

X^a is halogen,

Q is a six member aromatic structure containing 0–2 nitrogen, substituted or unsubstituted by halogen, up to per-halosubstitution;

Q^1 is a mono- or bicyclic aromatic structure of 3 to 10 carbon atoms and 0-4 members of the group consisting of N, O and S, unsubstituted or unsubstituted by halogen up to per-halosubstitution,

X, Z, n and n1 are as defined in claim 1, and s = 0 or 1.

4. A method as in claim 3, wherein

Q is phenyl or pyridinyl, substituted or unsubstituted by halogen, up to per-halosubstitution,

Q^1 is selected from the group consisting of phenyl, pyridinyl, naphthyl, pyrimidinyl, quinoline, isoquinoline, imidazole and benzothiazolyl, substituted or unsubstituted by halogen, up to per-halo substitution, or Y-Q^1 is phthalimidinyl substituted or unsubstituted by halogen up to per-halo substitution, and

Z and X are independently selected from the group consisting of $-R^6$, $-OR^6$ and $-NHR^7$, wherein R^6 is hydrogen, C_1-C_{10}-alkyl or C_3-C_{10}-cycloalkyl and R^7 is selected from the group consisting of hydrogen, C_3-C_{10}-alkyl, C_3-C_6-cycloalkyl and C_6-C_{10}-aryl, wherein R^6 and R^7 can be substituted by halogen or up to per-halosubstitution.

5. A method as in claim 1, comprising administering a compound of the formula



wherein R^1 and R^2 and B are as defined in claim 1.

6. A method as in claim 5, wherein B is of the formula



wherein Q is phenyl or pyridinyl, Q^1 is pyridinyl, phenyl or benzothiazolyl, Y is –O-,

-S-, -CH_2S-, -SCH_2-, -CH_2O-, -OCH_2- or –CH_2-, and Z is -SCH_3 or –NH-C(O)-C_pH_{2p+1}, wherein p is 1-4, n = 0, s = 1 and n1 = 0-1.

7. A method as in claim 1 comprising administering a compound selected from the group consisting of

N-(3-*tert*-Butyl-5-pyrazolyl)-*N'*-(4-phenyloxyphenyl)urea;
N-(3-*tert*-Butyl-5-pyrazolyl)-*N'*-(3-(3-methylaminocarbonylphenyl)oxyphenyl)urea;
N-(3-*tert*-Butyl-5-pyrazolyl)-*N'*-(3-(4-pyridinyl)thiophenyl)urea;
N-(3-*tert*-Butyl-5-pyrazolyl)-*N'*-(4-(4-pyridinyl)thiophenyl)urea;
N-(3-*tert*-Butyl-5-pyrazolyl)-*N'*-(4-(4-pyridinyl)oxyphenyl)urea;
N-(3-*tert*-Butyl-5-pyrazolyl)-*N'*-(4-(4-pyridinyl)methylphenyl)urea;
N-(1-Methyl-3-*tert*-butyl-5-pyrazolyl)-*N'*-(4-phenyloxyphenyl)urea;
N-(1-Methyl-3-*tert*-butyl-5-pyrazolyl)-*N'*-(3-(4-pyridinyl)thiophenyl)urea;
N-(1-Methyl-3-*tert*-butyl-5-pyrazolyl)-*N'*-((4-(4-pyridinyl)thiomethyl)phenyl)urea;
N-(1-Methyl-3-*tert*-butyl-5-pyrazolyl)-*N'*-(4-(4-pyridinyl)thiophenyl)urea;
N-(1-Methyl-3-*tert*-butyl-5-pyrazolyl)-*N'*-(4-(4-pyridinyl)oxyphenyl)urea;
N-(1-Methyl-3-*tert*-butyl-5-pyrazolyl)-*N'*-((4-(4-pyridinyl)methyloxy)phenyl)urea;
N-(1-Methyl-3-*tert*-butyl-5-pyrazolyl)-*N'*-(3-(2-benzothiazolyl)oxyphenyl)urea;
N-(3-*tert*-butyl-5-pyrazolyl)-*N'*-(3-(4-pyridyl)thiophenyl) urea;
N-(3-*tert*-butyl-5-pyrazolyl)-*N'*-(4-(4-pyridyl)thiophenyl) urea;
N-(3-*tert*-butyl-5-pyrazolyl)-*N'*-(3-(4-pyridyl)oxyphenyl) urea;
N-(3-*tert*-butyl-5-pyrazolyl)-*N'*-(4-(4-pyridyl)oxyphenyl) urea;
N-(1-methyl-3-*tert*-butyl-5-pyrazolyl)-*N'*-(3-(4-pyridyl)thiophenyl) urea;
N-(1-methyl-3-*tert*-butyl-5-pyrazolyl)-*N'*-(4-(4-pyridyl)thiophenyl) urea;
N-(1-methyl-3-*tert*-butyl-5-pyrazolyl)-*N'*-(3-(4-pyridyl)oxyphenyl) urea;
N-(1-methyl-3-*tert*-butyl-5-pyrazolyl)-*N'*-(4-(4-pyridyl)oxyphenyl) urea;

and pharamceutically acceptable salts thereof.

8. A method as in claim 5, wherein R^1 is t-butyl.

9. A method as in claim 1 comprising administering a compound of the formula



wherein R^1 and B are as defined in claim 1.

10. A method as in claim 9, wherein B is of the formula



Q is phenyl or pyridinyl, Q^1 is pyridinyl, phenyl or benzothiazolyl, Y is –O-, -S-, -C(O)- or $–CH_2-$, X is $–CH_3$ and Z is $–NH-C(O)-C_pH_{2p+1}$, wherein p is 1-4, $-CH_3$, -OH, $-OCH_3$, $-C_2H_5$, -CN or $–C(O)CH_3$, n = 0 or 1, s = 0 or 1 and n1 = 0 or 1.

11. A method as in claim 1 comprising administering a compound selected from the group consisting of:

N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(4-hydroxyphenyl)oxyphenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(3-hydroxyphenyl)oxyphenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(4-acetylphenyl)oxyphenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-benzoylphenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-phenyloxyphenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(3-methylaminocarbonylphenyl)-thiophenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(4-(1,2-methylenedioxy)phenyl)-oxyphenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(3-pyridinyl)oxyphenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(4-pyridinyl)oxyphenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(4-pyridyl)thiophenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(4-pyridinyl)methylphenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-(4-pyridinyl)oxyphenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-(4-pyridinyl)thiophenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-(3-methyl-4-pyridinyl)oxyphenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-(3-methyl-4-pyridinyl)thiophenyl)urea;

N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(3-methyl-4-pyridinyl)thiophenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-(4-methyl-3-pyridinyl)oxyphenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(3-methyl-4-pyridinyl)oxyphenyl)urea;
N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-(2-benzothiazolyl)oxyphenyl)urea;

N-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(3-chloro-4-(4-(2-methylcarbamoyl)pyridyl)-oxyphenyl) urea;

N-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(4-(4-(2-methylcarbamoyl)pyridyl)-oxyphenyl) urea;

N-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(3-(4-(2-methylcarbamoyl)pyridyl)-thiophenyl) urea;

N-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(2-methyl-4-(4-(2-methylcarbamoyl)pyridyl)-oxyphenyl) urea;

N-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(4-(4-(2-carbamoyl)pyridyl)oxyphenyl) urea;

N-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(3-(4-(2-carbamoyl)pyridyl)oxyphenyl) urea;

N-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(3-(4-(2-methylcarbamoyl)pyridyl)-oxyphenyl) urea;

N-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(4-(4-(2-methylcarbamoyl)pyridyl)-thiophenyl) urea;

N-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(3-chloro-4-(4-(2-methylcarbamoyl)pyridyl)-oxyphenyl) urea;

N-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(4-(3-methylcarbamoyl)phenyl)oxyphenyl) urea; and pharmaceutically acceptable salts thereof.

12. A method as in claim 10, wherein R^1 is t-butyl.

13. A method as in claim 1 comprising administering a compound of the formula



wherein R^1 and B are as defined in claim 1.

14. A method as in claim 13, wherein B is of the formula



Q is is phenyl or pyridinyl, Q^1 is phenyl, benzothiazolyl or pyridinyl, Y is –O-, -S- or $-CH_2-$, Z is $-CH_3$, -Cl, $-OC_2H_5$ or $-OCH_3$, n = 0, s = 1, and n1 = 0 or 1.

15. A method as in claim 1 comprising administering a compound selected from the group consisting of

N-(3-Isopropyl-5-isoxazolyl)-*N'*-(4-(4-pyridinyl)thiophenyl)urea;

N-(3-*tert*-Butyl-5-isoxazolyl)-*N'*-(4-(4-methoxyphenyl)oxyphenyl)urea;

N-(3-*tert*-Butyl-5-isoxazolyl)-*N'*-(5-(2-(4-acetylphenyl)oxy)pyridinyl)urea;

N-(3-*tert*-Butyl-5-isoxazolyl)-*N'*-(3-(4-pyridinyl)thiophenyl)urea;

N-(3-*tert*-Butyl-5-isoxazolyl)-*N'*-(4-(4-pyridinyl)methylphenyl)urea;

N-(3-*tert*-Butyl-5-isoxazolyl)-*N'*-(4-(4-pyridinyl)thiophenyl)urea;

N-(3-*tert*-Butyl-5-isoxazolyl)-*N'*-(4-(4-pyridinyl)oxyphenyl)urea;

N-(3-*tert*-Butyl-5-isoxazolyl)-*N'*-(4-(4-methyl-3-pyridinyl)oxyphenyl)urea;

N-(3-*tert*-Butyl-5-isoxazolyl)-*N'*-(3-(2-benzothiazolyl)oxyphenyl)urea;

N-(3-(1,1-Dimethylpropyl)-5-isoxazolyl)-*N'*-(4-(4-methylphenyl)oxyphenyl)urea;

N-(3-(1,1-Dimethylpropyl)-5-isoxazolyl)-*N'*-(3-(4-pyridinyl)thiophenyl)urea;

N-(3-(1,1-Dimethylpropyl)-5-isoxazolyl)-*N'*-(4-(4-pyridinyl)oxyphenyl)urea;

N-(3-(1,1-Dimethylpropyl)-5-isoxazolyl)-*N'*-(4-(4-pyridinyl)thiophenyl)urea;

N-(3-(1,1-Dimethylpropyl-5-isoxazolyl)-*N'*-(5-(2-(4-methoxyphenyl)oxy)pyridinyl)urea;

N-(3-(1-Methyl-1-ethylpropyl)-5-isoxazolyl)-*N'*-(4-(4-pyridinyl)oxyphenyl)urea;

N-(3-(1-Methyl-1-ethylpropyl)-5-isoxazolyl)-*N'*-(3-(4-pyridinyl)thiophenyl)urea;

N-(3-isopropyl-5-isoxazolyl)-*N'*-(3-(4-(2-methylcarbamoyl)pyridyl)-oxyphenyl) urea;

N-(3-isopropyl-5-isoxazolyl)-*N'*-(4-(4-(2-methylcarbamoyl)pyridyl)-oxyphenyl) urea;

N-(3-*tert*-butyl-5-isoxazolyl)-*N'*-(3-(4-(2-methylcarbamoyl)pyridyl)-oxyphenyl) urea;

N-(3-*tert*-butyl-5-isoxazolyl)-*N'*-(4-(4-(2-methylcarbamoyl)pyridyl)-oxyphenyl) urea;

N-(3-*tert*-butyl-5-isoxazolyl)-*N'*-(3-(4-(2-methylcarbamoyl)pyridyl)-thiophenyl) urea;

N-(3-(1,1-dimethylprop-1-yl)-5-isoxazolyl)-*N'*-(3-(4-(2-methylcarbamoyl)pyridyl)-oxyphenyl) urea;

N-(3-(1,1-dimethylprop-1-yl)-5-isoxazolyl)-*N'*-(4-(4-(2-methylcarbamoyl)pyridyl)-oxyphenyl) urea

N-(3-*tert*-butyl-5-isoxazolyl)-*N'*-(3-chloro-4-(4-(2-methylcarbamoyl)pyridyl)-thiophenyl) urea

and pharmaceutically acceptable salts thereof.

16. A method as in claim 13, wherein R^1 is t-butyl.

17. A method as in claim 1 comprising administering a compound of the formula



wherein R^1, R^b and B are as defined in claim 1.

18. A method as in claim 17, wherein B is of the formula



wherein Q is phenyl, Q^1 is phenyl or pyridinyl, Y is –O- or -S-, Z is –Cl, $-CH_3$, -OH or OCH_3, n = 0, s = 0 or 1 and n1 = 0-2.

19. A method as in claim 1 comprising administering a compound selected from the group consisting of:

N-(5-*tert*-Butyl-3-thienyl)-*N'*-(4-(3-methylphenyl)oxyphenyl)urea;

N-(5-*tert*-Butyl-3-thienyl)-*N'*-(4-(4-hydroxyphenyl)oxyphenyl)urea;

N-(5-*tert*-Butyl-3-thienyl)-*N'*-(4-(4-methoxyphenyl)oxyphenyl)urea;

N-(5-*tert*-Butyl-3-thienyl)-*N'*-(4-(4-pyridinyl)thiophenyl)urea;

and pharmaceutically acceptable salts thereof.

20. A method as in claim 17, wherein R^1 is t-butyl.

21. A method as in claim 1 comprising administering a compound of the formula



wherein R^a and B are as defined in claim 1.

22. A method as in claim 21, wherein B is of the formula



wherein Q is phenyl, Q^1 is phenyl or pyridinyl, Y is –O- or –S-, s = 1, n = 0 and n1 = 0.

23. A method as in claim 2 comprising administering a compound selected from the group consisting of:

N-(5-*tert*-Butyl-2-(1-thia-3,4-diazolyl))-*N'*-(3-(4-pyridinyl)thiophenyl)urea;

N-(5-*tert*-Butyl-2-(1-thia-3,4-diazolyl))-*N'*-(4-(4-pyridinyl)oxyphenyl)urea;

and pharmaceutically acceptable salts thereof.

24. A method as in claim 21, wherein R^a is CF_3- or t-butyl.

25. A method as in claim 1 comprising administering a compound of one of the formulae



or



wherein R^1 and B are as defined in claim 1.

26. A method as in claim 25, wherein B is up to per-halosubstituted phenyl, up to perhalosubstituted pyridinyl, or of the formula



wherein Q is phenyl, Q^1 is phenyl or pyridinyl, and Y is –O- or -S-, Z is –Cl, $-CH_3$, -OH or $-OCH_3$, n = 0, s = 0 or 1 and n1 = 0-2.

27. A method as in claim 25, wherein R^1 is t-butyl.

28. A method as in claim 1, comprising administering a compound of the formulae



wherein R^1 and R^b and B are as defined in claim 1.

29. A method as in claim 28, wherein B is of the formula



wherein Q is phenyl, Q^1 is phenyl or pyridinyl, and Y is –O- or -S-, Z is –Cl or $-OCH_3$, n = 0, s = 0 or 1 and n1 = 0-2.

30. A method as in claim 28, wherein R^1 is t-butyl.

31. A compound of the formula



wherein R^2 is selected from the group consisting of H, $-C(O)R^4$, $-CO_2R^4$, $-C(O)NR^3R^{3'}$, C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, C_7-C_{24} alkaryl, C_4-C_{23} alkheteroaryl, substituted C_1-C_{10} alkyl, substituted C_3-C_{10} cycloalkyl, substituted C_7-C_{24} alkaryl and substituted C_4-C_{23} alkheteroaryl, where if R^2 is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of -CN, $-CO_2R^4$, $-C(O)-NR^3R^{3'}$, $-NO_2$, $-OR^4$, $-SR^4$, and halogen up to per-halosubstitution,

wherein R^3 and $R^{3'}$ are independently selected from the group consisting of H, $-OR^4$, $-SR^4$, $-NR^4R^{4'}$, $-C(O)R^4$, $-CO_2R^4$, $-C(O)NR^4R^{4'}$, C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, C_3-C_{13} heteroaryl, C_7-C_{24} alkaryl, C_4-C_{23} alkheteroaryl, up to per-halosubstituted C_1-C_{10} alkyl, up to per-halosubstituted C_3-C_{10} cycloalkyl, up to per-halosubstituted C_6-C_{14} aryl and up to per-halosubstituted C_3-C_{13} heteroaryl; and

wherein R^4 and $R^{4'}$ are independently selected from the group consisting of H, C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, C_3-C_{13} heteroaryl; C_7-C_{24} alkaryl, C_4-C_{23} alkheteroaryl, up to per-halosubstituted C_1-C_{10} alkyl, up to per-halosubstituted C_3-C_{10} cycloalkyl, up to per-halosubstituted C_6-C_{14} aryl and up to per-halosubstituted C_3-C_{13} heteroaryl,

wherein R^1 is selected from the group consisting of halogen, C_3-C_{10} alkyl, $C_{1\text{-}13}$ heteroaryl, C_6-C_{14} aryl, C_7-C_{24} alkaryl, C_3-C_{10} cycloalkyl, up to per-halosubstituted C_1-C_{10} alkyl and up to per-halosubstituted C_3-C_{10} cycloalkyl, up to per-halosubstituted $C_{1\text{-}13}$-heteroaryl, up to per-halosubstituted $C_{6\text{-}14}$-aryl , and up to per-halosubstituted $C_{7\text{-}24}$-alkaryl;

R^c is hydrogen, halogen, $C_{1\text{-}10}$-alkyl, up to per-halosubstituted $C_{1\text{-}10}$-alkyl or combines with R^1 and the ring carbon atoms to which R^1 and R^c are bound to form a 5 or 6 member cycloalkyl, aryl or heteroaryl ring with 0-2 members selected from O, N, and S,

B is up to a tricyclic aromatic ring structure selected from the group consisting of:







which is substituted or unsubstituted by halogen, up to per-halosubstitution, and wherein n = 0-2; each X^1 is independently selected from the group of X or from the group consisting of –CN, $-CO_2R^5$, $-C(O)R^5$, $-C(O)NR^5R^{5'}$, $-OR^5$, $-NO_2$, $-NR^5R^{5'}$, C_1-C_{10} alkyl, C_{2-10}-alkenyl, C_{1-10}-alkoxy, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl and C_7-C_{24} alkaryl, and X is selected from the group consisting of $-SR^5$, $-NR^5C(O)OR^{5'}$, $NR^5C(O)R^{5'}$, C_3-C_{13} heteroaryl, C_4-C_{23} alkheteroaryl, substituted C_1-C_{10} alkyl, substituted C_{2-10}-alkenyl, substituted C_{1-10}-alkoxy, substituted C_3-C_{10} cycloalkyl, substituted C_6-C_{14} aryl, substituted C_7-C_{24} alkaryl, substituted C_3-C_{13} heteroaryl, substituted C_4-C_{23} alkheteroaryl, and –Y-Ar,

wherein if X is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of –CN, $-CO_2R^5$, $-C(O)R^5$, $-C(O)NR^5R^{5'}$, $-OR^5$, $-SR^5$, $-NR^5R^{5'}$, NO_2, $-NR^5C(O)R^{5'}$, $-NR^5C(O)OR^{5'}$ and halogen up to per-halosubstitution;

wherein R^5 and $R^{5'}$ are independently selected from H, C_1-C_{10} alkyl, C_{2-10}-alkenyl, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, C_3-C_{13} heteroaryl, C_7-C_{24} alkaryl, C_4-C_{23} alkheteroaryl, up to per-halosubstituted C_1-C_{10} alkyl; up to per-halosubstituted C_{2-10}-alkenyl; up to per-halosubstituted C_3-C_{10} cycloalkyl, up to per-halosubstituted C_6-C_{14} aryl and up to per-halosubstituted C_3-C_{13} heteroaryl,

wherein Y is -O-, -S-, $-N(R^5)$-, $-(CH_2)_m$-, -C(O)-, -CH(OH)-, $-(CH_2)_mO$-, $-NR^5C(O)NR^5R^{5'}$-, $-NR^5C(O)$-, $-C(O)NR^5$-, $-(CH_2)_mS$-, $-(CH_2)_mN(R^5)$-, $-O(CH_2)_m$-, $-CHX^a$, $-CX^a_2$-, $-S-(CH_2)_m$- and $-N(R^5)(CH_2)_m$-,

m = 1-3, and X^a is halogen; and

Ar is a 5-10 member aromatic structure containing 0-2 members of the group consisting of nitrogen, oxygen and sulfur which is unsubstituted or substituted by

halogen up to per-halo and optionally substituted by Z_{n1}, wherein n1 is 0 to 3 and each Z is independently selected from the group consisting of –CN, $-CO_2R^5$, $-C(O)R^5$, =O, $-C(O)NR^5R^{5'}$, $-C(O)R^5$, $-NO_2$, $-OR^5$, $-SR^5$, $-NR^5R^{5'}$, $-NR^5C(O)OR^{5'}$, $-NR^5C(O)R^{5'}$, $-SO_2R^5$, $-SO_2R^5$ $R^{5'}$ C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, C_3-C_{13} heteroaryl, C_7-C_{24} alkaryl, C_4-C_{23} alkheteroaryl, substituted C_1-C_{10} alkyl, substituted C_3-C_{10} cycloalkyl, substituted C_7-C_{24} alkaryl and substituted C_4-C_{23} alkheteroaryl; wherein if Z is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of –CN, $-CO_2R^5$, $-C(O)NR^5R^{5'}$, =O, $-OR^5$, $-SR^5$, $-NO_2$, $-NR^5R^{5'}$, $-NR^5C(O)R^{5'}$, $-NR^5C(O)OR^{5'}$, C_1-C_{10} alkyl, C_1-C_{10} alkoxyl, C_3-C_{10} cycloalkyl, , C_3-C_{13} heteroaryl, C_6-C_{14} aryl, C_4-C_{24} alkheteroaryl ,and C_7-C_{24} alkaryl, subject to the proviso that where R^1 is t-butyl and R^2 is methly, B is not



32. A compound of claim 31, wherein B is



wherein

Y is selected from the group consisting of –O-, -S-, $-CH_2$-, $-SCH_2$-, $-CH_2S$-, -CH(OH)-, -C(O)-, $-CX^a_2$, $-CX^aH$-, $-CH_2O$-, and $-OCH_2$-,

X^a is halogen,

Q is a six member aromatic structure containing 0–2 nitrogen, substituted or unsubstituted by halogen, up to per-halosubstitution;

Q^1 is a mono- or bicyclic aromatic structure of 3 to 10 carbon atoms and 0-4 members of the group consisting of N, O and S, unsubstituted or unsubstituted by halogen up to per-halosubstitution,

X, Z, n and n1 are as defined in claim 31 and s = 0 or 1.

33. A compound of claim 32, wherein

Q is phenyl or pyridinyl, substituted or unsubstituted by halogen, up to per-halosubstitution,

Q^1 is selected from the group consisting of phenyl, pyridinyl, naphthyl, pyrimidinyl, quinoline, isoquinoline, imidazole and benzothiazolyl, substituted or unsubstituted by halogen, up to per-halo, or -Y-Q^1 is phthalimidinyl substituted or unsubstituted by halogen up to per-halosubstitution, and

Z and X are independently selected from the group consisting of $-R^6$, $-OR^6$ and $-NHR^7$, wherein R^6 is hydrogen, C_1-C_{10}-alkyl or C_3-C_{10}-cycloalkyl and R^7 is selected from the group consisting of hydrogen, C_3-C_{10}-alkyl, C_3-C_6-cycloalkyl and C_6-C_{10}-aryl, wherein R^6 and R^7 can be substituted by halogen or up to per-halosubstitution.

34. A compound of claim 32, wherein Q is phenyl or pyridinyl, Q^1 is pyridinyl, phenyl or benzothiazolyl, Y is –O-, -S-, $-CH_2S-$, $-SCH_2-$, $-CH_2O-$, $-OCH_2-$ or $-CH_2-$, and Z is $-SCH_3$, or $-NH-C(O)-C_pH_{2p+1}$, wherein p is 1-4, n = 0, s = 1 and n1 = 0-1.

35. A compound of claim 31 of the formula



wherein R^2 and B are as defined in claim 31.

36. A compound as in claim 31 selected from the group consisting of:

N-(3-*tert*-Butyl-5-pyrazolyl)-*N'*-(4-phenyloxyphenyl)urea;

N-(3-*tert*-Butyl-5-pyrazolyl)-*N'*-(3-(3-methylaminocarbonylphenyl)oxyphenyl)urea;

N-(3-*tert*-Butyl-5-pyrazolyl)-*N'*-(3-(4-pyridinyl)thiophenyl)urea;

N-(3-*tert*-Butyl-5-pyrazolyl)-*N'*-(4-(4-pyridinyl)thiophenyl)urea;

N-(3-*tert*-Butyl-5-pyrazolyl)-*N'*-(4-(4-pyridinyl)oxyphenyl)urea;

N-(3-*tert*-Butyl-5-pyrazolyl)-*N'*-(4-(4-pyridinyl)methylphenyl)urea;

N-(1-Methyl-3-*tert*-butyl-5-pyrazolyl)-*N'*-(4-phenyloxyphenyl)urea;

N-(1-Methyl-3-*tert*-butyl-5-pyrazolyl)-*N'*-(3-(4-pyridinyl)thiophenyl)urea;

N-(1-Methyl-3-*tert*-butyl-5-pyrazolyl)-*N'*-((4-(4-pyridinyl)thiomethyl)phenyl)urea;

N-(1-Methyl-3-*tert*-butyl-5-pyrazolyl)-*N'*-(4-(4-pyridinyl)thiophenyl)urea;

N-(1-Methyl-3-*tert*-butyl-5-pyrazolyl)-*N'*-(4-(4-pyridinyl)oxyphenyl)urea;

N-(1-Methyl-3-*tert*-butyl-5-pyrazolyl)-*N'*-((4-(4-pyridinyl)methyloxy)phenyl)urea;

N-(1-Methyl-3-*tert*-butyl-5-pyrazolyl)-*N'*-(3-(2-benzothiazolyl)oxyphenyl)urea;

N-(3-*tert*-butyl-5-pyrazolyl)-*N'*-(3-(4-pyridyl)thiophenyl) urea;

N-(3-*tert*-butyl-5-pyrazolyl)-*N'*-(4-(4-pyridyl)thiophenyl) urea;

N-(3-*tert*-butyl-5-pyrazolyl)-*N'*-(3-(4-pyridyl)oxyphenyl) urea;

N-(3-*tert*-butyl-5-pyrazolyl)-*N'*-(4-(4-pyridyl)oxyphenyl) urea;

N-(1-methyl-3-*tert*-butyl-5-pyrazolyl)-*N'*-(3-(4-pyridyl)thiophenyl) urea;

N-(1-methyl-3-*tert*-butyl-5-pyrazolyl)-*N'*-(4-(4-pyridyl)thiophenyl) urea;

N-(1-methyl-3-*tert*-butyl-5-pyrazolyl)-*N'*-(3-(4-pyridyl)oxyphenyl) urea;

N-(1-methyl-3-*tert*-butyl-5-pyrazolyl)-*N'*-(4-(4-pyridyl)oxyphenyl) urea;

and pharmaceutically acceptable salts thereof.

37. A compound of the formula



wherein R^1 is selected from the group consisting of halogen,C_3-C_{10} alkyl, C_3-C_{10} cycloalkyl,

C_{1-13}-heteroaryl, C_{6-14}-aryl, C_{7-24}-alkaryl, up to per-halosubstituted C_1-C_{10} alkyl and per-halosubstituted C_3-C_{10} cycloalkyl, up to per-halosubstituted C_{1-13}-heteroaryl, up to per-halosubstituted C_{6-14}-aryl, and up to per-halosubstituted C_{7-24}-alkaryl;

B is up to a tricyclic aromatic ring structure selected from the group consisting of



which is substituted or unsubstituted by halogen, up to per-halosubstitution, and wherein n = 0-2;

each X^1 is independently selected from the group of X or from the group consisting of –CN, $-CO_2R^5$, $-C(O)R^5$, $-C(O)NR^5R^{5'}$, $-OR^5$, $-NO_2$, $-NR^5R^{5'}$, C_1-C_{10} alkyl, C_{2-10}-alkenyl, C_{1-10}-alkoxy, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl and C_7-C_{24} alkaryl, and

X is selected from the group consisting of $-SR^5$, $-NR^5C(O)OR^{5'}$, $NR^5C(O)R^{5'}$, C_3-C_{13} heteroaryl, C_4-C_{23} alkheteroaryl, substituted C_1-C_{10} alkyl, substituted C_{2-10}-alkenyl, substituted C_{1-10}-alkoxy, substituted C_3-C_{10} cycloalkyl, substituted C_6-C_{14} aryl, substituted C_7-C_{24} alkaryl, substituted C_3-C_{13} heteroaryl, substituted C_4-C_{23} alkheteroaryl, and –Y-Ar, and

wherein if X is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of –CN, $-CO_2R^5$, $-C(O)R^5$, $-C(O)NR^5R^{5'}$, $-OR^5$, $-SR^5$, $-NR^5R^{5'}$, NO_2, $-NR^5C(O)R^{5'}$, $-NR^5C(O)OR^{5'}$ and halogen up to per-halosubstitution;

wherein R^5 and $R^{5'}$ are independently selected from H, C_1-C_{10} alkyl, C_{2-10}-alkenyl, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, C_3-C_{13} heteroaryl, C_7-C_{24} alkaryl, C_4-C_{23} alkheteroaryl, up to per-halosubstituted C_1-C_{10} alkyl, up to per-halosubstituted C_{2-10}-alkenyl, up to per-halosubstituted C_3-C_{10} cycloalkyl, up to per-halosubstituted C_6-C_{14} aryl and up to per-halosubstituted C_3-C_{13} heteroaryl,

wherein Y is - O-, -S-, -N(R^5)-, -(CH_2)-$_m$, -C(O)-, -CH(OH)-, -(CH_2)$_m$O-, -$NR^5C(O)NR^5R^{5'}$-, -$NR^5C(O)$-, -$C(O)NR^5$-, -(CH_2)$_m$S-, -(CH_2)$_m$N(R^5)-, -O(CH_2)$_m$-, -CHX^a, -CX^a_2-, -S-(CH_2)$_m$- and -N(R^5)(CH_2)$_m$-,

m = 1-3, and X^a is halogen; and

Ar is a 5-10 member aromatic structure containing 0-2 members of the group consisting of nitrogen, oxygen and sulfur which is unsubstituted or substituted by halogen up to per-halo and optionally substituted by Z_{n1}, wherein nl is 0 to 3 and each Z is independently selected from the group consisting of –CN, -CO_2R^5, -$C(O)R^5$, =O, -$C(O)NR^5R^{5'}$, -$C(O)R^5$, -NO_2, -OR^5, - SR^5, - $NR^5R^{5'}$, -$NR^5C(O)OR^{5'}$, -$NR^5C(O)R^{5'}$, -SO_2R^5, -SO_2 R^5 $R^{5'}$, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, C_3-C_{13} heteroaryl, C_7-C_{24} alkaryl, C_4-C_{23} alkheteroaryl, substituted C_1-C_{10} alkyl, substituted C_3-C_{10} cycloalkyl, substituted C_7-C_{24} alkaryl and substituted C_4-C_{23} alkheteroaryl; wherein if Z is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of –CN, -CO_2R^5, -$C(O)NR^5R^{5'}$, =O, -OR^5, -SR^5, -NO_2, -$NR^5R^{5'}$, -$NR^5C(O)R^{5'}$, -$NR^5C(O)OR^{5'}$, C_1-C_{10} alkyl, C_1-C_{10} alkoxyl, C_3-C_{10} cycloalkyl, , C_3-C_{13} heteroaryl, C_6-C_{14} aryl, C_4-C_{24} alkheteroaryl ,and C_7-C_{24} alkaryl,

subject to the proviso that where R^1 is t-butyl,

B is not



wherein R^6 is -NHC(O)-O-t-butyl, -O-n-pentyl, -O-n-butyl, -O-n-propyl, -$C(O)NH$-(CH_3)$_2$, -$OCH_2CH(CH_3)_2$, or



38. A compound of claim 37, wherein B is

wherein



Y is selected from the group consisting of –O-, -S-, -CH_2-, -SCH_2-, -CH_2S-, -CH(OH)-, -C(O)-, -CX^a_2, -CX^aH-, -CH_2O- and -OCH_2-,

X^a is halogen,

Q is a six member aromatic structure containing 0–2 nitrogen; substituted or unsubstituted by halogen, up to per-halosubstitution;

Q^1 is a mono- or bicyclic aromatic structure of 3 to 10 carbon atoms and 0-4 members of the group consisting of N, O and S, unsubstituted or unsubstituted by halogen up to per-halosubstitution,

X, Z, n and n1 are as defined in claim 37 and s = 0 or 1.

39. A compound of claim 38, wherein

Q is phenyl or pyridinyl, substituted or unsubstituted by halogen, up to per-halosubstitution,

Q^1 is selected from the group consisting of phenyl, pyridinyl, naphthyl, pyrimidinyl, quinoline, isoquinoline, imidazole and benzothiazolyl, substituted or unsubstituted by halogen, up to per-halo, or -Y-Q^1 is phthalimidinyl substituted or unsubstituted by halogen up to per-halosubstitution, and

Z and X are independently selected from the group consisting of –R^6, -OR^6 and –NHR^7, wherein R^6 is hydrogen, C_1-C_{10}-alkyl or C_3-C_{10}-cycloalkyl and R^7 is selected from the group consisting of hydrogen, C_3-C_{10}-alkyl, C_3-C_6-cycloalkyl and C_6-C_{10}-aryl, wherein R^6 and R^7 can be substituted by halogen or up to per-halosubstitution.

40. A compound of claim 38, wherein Q is phenyl or pyridinyl, Q^1 is pyridinyl, phenyl or benzothiazolyl, Y is –O-, -S-, -C(O)- or –CH_2-, and Z is–NH-C(O)-C_pH_{2p+1}, wherein p is 1-4, -CH_3, -OH, -OCH_3, -OC_2H_5, -CN or –$C(O)CH_3$, n = 0 or 1, s = 0 or 1 and n1 = 0 or 1.

41. A compound as in claim 22 selected from the group consisting of:

N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(4-hydroxyphenyl)oxyphenyl)urea;

N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(3-hydroxyphenyl)oxyphenyl)urea;

N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(4-acetylphenyl)oxyphenyl)urea;

N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-benzoylphenyl)urea;

N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-phenyloxyphenyl)urea;

N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(3-methylaminocarbonylphenyl)-thiophenyl)urea;

N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(4-(1,2-methylenedioxy)phenyl)-oxyphenyl)urea;

N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(3-pyridinyl)oxyphenyl)urea;

N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(4-pyridinyl)oxyphenyl)urea;

N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(4-pyridyl)thiophenyl)urea;

N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(4-pyridinyl)methylphenyl)urea;

N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-(4-pyridinyl)oxyphenyl)urea;

N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-(4-pyridinyl)thiophenyl)urea;

N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-(3-methyl-4-pyridinyl)oxyphenyl)urea;

N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-(3-methyl-4-pyridinyl)thiophenyl)urea;

N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(3-methyl-4-pyridinyl)thiophenyl)urea;

N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-(4-methyl-3-pyridinyl)oxyphenyl)urea;

N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(4-(3-methyl-4-pyridinyl)oxyphenyl)urea;

N-(5-*tert*-Butyl-3-isoxazolyl)-*N'*-(3-(2-benzothiazolyl)oxyphenyl)urea;

N-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(3-chloro-4-(4-(2-methylcarbamoyl)pyridyl)-oxyphenyl) urea;

N-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(4-(4-(2-methylcarbamoyl)pyridyl)-oxyphenyl) urea;

N-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(3-(4-(2-methylcarbamoyl)pyridyl)-thiophenyl) urea;

N-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(2-methyl-4-(4-(2-methylcarbamoyl)pyridyl)-oxyphenyl) urea;

N-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(4-(4-(2-carbamoyl)pyridyl)oxyphenyl) urea;

N-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(3-(4-(2-carbamoyl)pyridyl)oxyphenyl) urea;

N-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(3-(4-(2-methylcarbamoyl)pyridyl)-oxyphenyl) urea;

N-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(4-(4-(2-methylcarbamoyl)pyridyl)-thiophenyl) urea;

N-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(3-chloro-4-(4-(2-methylcarbamoyl)pyridyl)-oxyphenyl) urea;

N-(5-*tert*-butyl-3-isoxazolyl)-*N'*-(4-(3-methylcarbamoyl)phenyl)oxyphenyl) urea;

and pharmaceutically acceptable salts thereof.

42. A compound of claim 37 of the formula



wherein B is as defined in claim 37.

43. A compound of the formula



wherein R^1 is selected from the group consisting of halogen, C_3-C_{10} alkyl, C_{1-13}-heteroaryl, C_{6-14}-aryl, C_{7-24}-alkaryl, C_3-C_{10} cycloalkyl, up to per-halosubstituted C_1-C_{10} alkyl, per-halosubstituted C_3-C_{10} cycloalkyl, up to per-halosubstituted C_{1-13}-heteroaryl, up to per-halosubstituted C_{6-14}-aryl, and up to per-halosubstituted C_{7-24}-alkaryl; and

B is an aromatic ring structure selected from the group consisting of



;

which is substituted or unsubstituted by halogen, up to per-halosubstitution, and wherein n = 0-2;

each X^1 is independently selected from the group of X or from the group consisting of –CN, $-CO_2R^5$, $-C(O)R^5$, $-C(O)NR^5R^{5'}$, $-OR^5$, $-NO_2$, $-NR^5R^{5'}$, C_1-C_{10} alkyl, C_{2-10}-alkenyl, C_{1-10}-alkoxy, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl and C_7-C_{24} alkaryl, and

X is selected from the group consisting of $-SR^5$, $-NR^5C(O)OR^{5'}$, $NR^5C(O)R^{5'}$, C_3-C_{13} heteroaryl, C_4-C_{23} alkheteroaryl, substituted C_1-C_{10} alkyl, substituted C_{2-10}-alkenyl, substituted C_{1-10}-alkoxy, substituted C_3-C_{10} cycloalkyl, substituted C_6-C_{14} aryl, substituted C_7-C_{24} alkaryl, substituted C_3-C_{13} heteroaryl, substituted C_4-C_{23} alkheteroaryl, and –Y-Ar, and wherein if X is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of –CN, $-CO_2R^5$, $-C(O)R^5$, $-C(O)NR^5R^{5'}$, $-OR^5$, $-SR^5$, $-NR^5R^{5'}$, NO_2, $-NR^5C(O)R^{5'}$, $-NR^5C(O)OR^{5'}$ and halogen up to per-halosubstitution;

wherein R^5 and $R^{5'}$ are independently selected from H, C_1-C_{10} alkyl, C_{2-10}-alkenyl, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, C_3-C_{13} heteroaryl, C_7-C_{24} alkaryl, C_4-C_{23} alkheteroaryl, up to per-halosubstituted C_1-C_{10} alkyl, up to per-halosubstituted C_{2-10}-alkenyl, up to per-halosubstituted C_3-C_{10} cycloalkyl, up to per-halosubstituted C_6-C_{14} aryl and up to per-halosubstituted C_3-C_{13} heteroaryl,

wherein Y is - O-, -S-, $-N(R^5)-$, $-(CH_2)_m-$, -C(O)-, -CH(OH)-, $-(CH_2)_mO-$, $-NR^5C(O)NR^5R^{5'}-$, $-NR^5C(O)-$, $-C(O)NR^5-$, $-(CH_2)_mS-$, $-(CH_2)_mN(R^5)-$, $-O(CH_2)_m-$, $-CHX^a-$, $-CX^a_2-$; $-S-(CH_2)_m-$ and $-N(R^5)(CH_2)_m-$,

m = 1-3, and X^a is halogen; and

Ar is a 5- or 6-member aromatic structure containing 0-2 members of the group consisting of nitrogen, oxygen and sulfur which is unsubstituted or substituted by halogen up to per-halo and optionally substituted by Z_{n1}, wherein nl is 0 to 3 and each Z is independently selected from the group consisting of –CN, $-CO_2R^5$, $-C(O)R^5$, =O, $-C(O)NR^5R^{5'}$, $-C(O)R^5$, $-NO_2$, $-OR^5$, $-SR^5$, $-NR^5R^{5'}$, $-NR^5C(O)OR^{5'}$, $-NR^5C(O)R^{5'}$, $-SO_2R^5$, $-SO_2R^5R^{5'}$, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, C_3-C_{13} heteroaryl, C_7-C_{24} alkaryl, C_4-C_{23} alkheteroaryl, substituted C_1-C_{10} alkyl, substituted C_3-C_{10} cycloalkyl, substituted C_7-C_{24} alkaryl and substituted C_4-C_{23} alkheteroaryl; wherein if Z is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of –CN, $-CO_2R^5$, $-C(O)NR^5R^{5'}$, =O,

$-OR^5$, $-SR^5$, $-NO_2$, $-NR^5R^{5'}$, $-NR^5C(O)R^{5'}$ and $-NR^5C(O)OR^{5'}$, C_1-C_{10} alkyl, C_1-C_{10} alkoxyl, C_3-C_{10} cycloalkyl, , C_3-C_{13} heteroaryl, C_6-C_{14} aryl, C_4-C_{24} alkheteroaryl ,and C_7-C_{24} alkaryl,

and where R^1 is t-butyl, B is not



and where R^1 is $-CH_2$-t-butyl,

B is not



44. A compound of claim 43, wherein B is



wherein

Y is selected from the group consisting of –O-, -S-, $-CH_2$-, $-SCH_2$-, $-CH_2S$-, -CH(OH)-, -C(O)-, $-CX^a_2$, $-CX^aH$-, $-CH_2O$- and $-OCH_2$-,

X^a is halogen,

Q is a six member aromatic structure containing 0–4 nitrogen, substituted or unsubstituted by halogen, up to per-halosubstitution;

Q^1 is a mono- or bicyclic aromatic structure of 3 to 10 carbon atoms and 0-2 members of the group consisting of N, O and S, unsubstituted or unsubstituted by halogen up to per-halosubstitution,

X, Z, n and n1 are as defined in claim 43 and s = 0 or 1.

45. A compound of claim 44, wherein

Q is phenyl or pyridinyl, substituted or unsubstituted by halogen, up to per-halosubstitution,

Q^1 is selected from the group consisting of phenyl, pyridinyl, naphthyl, pyrimidinyl, quinoline, isoquinoline, imidazole and benzothiazolyl, substituted or unsubstituted by halogen, up to per-halo, or $-Y-Q^1$ is phthalimidinyl substituted or unsubstituted by halogen up to per-halosubstitution, and

Z and X are independently selected from the group consisting of $-R^6$, $-OR^6$ and $-NHR^7$, wherein R^6 is hydrogen, C_1-C_{10}-alkyl or C_3-C_{10}-cycloalkyl and R^7 is selected from the group consisting of hydrogen, C_3-C_{10}-alkyl, C_3-C_6-cycloalkyl and C_6-C_{10}-aryl, wherein R^6 and R^7 can be substituted by halogen or up to per-halosubstitution.

46. A compound of claim 43 of the formula



wherein B is as defined in claim 43.

47. A compound of claim 44, wherein Q is is phenyl or pyridinyl, Q^1 is phenyl, benzothiazolyl or pyridinyl, Y is –O-, -S- or $-CH_2-$, Z is $-CH_3$, -Cl-, OC_2H_5 or $-OCH_3$, n = 0, s = 1, and n1 = 0 or 1.

48. A compound as in claim 43 selected from the group consisting of:

N-(3-Isopropyl-5-isoxazolyl)-*N'*-(4-(4-pyridinyl)thiophenyl)urea;
N-(3-*tert*-Butyl-5-isoxazolyl)-*N'*-(4-(4-methoxyphenyl)oxyphenyl)urea;
N-(3-*tert*-Butyl-5-isoxazolyl)-*N'*-(5-(2-(4-acetylphenyl)oxy)pyridinyl)urea;
N-(3-*tert*-Butyl-5-isoxazolyl)-*N'*-(3-(4-pyridinyl)thiophenyl)urea;
N-(3-*tert*-Butyl-5-isoxazolyl)-*N'*-(4-(4-pyridinyl)methylphenyl)urea;
N-(3-*tert*-Butyl-5-isoxazolyl)-*N'*-(4-(4-pyridinyl)thiophenyl)urea;
N-(3-*tert*-Butyl-5-isoxazolyl)-*N'*-(4-(4-pyridinyl)oxyphenyl)urea;
N-(3-*tert*-Butyl-5-isoxazolyl)-*N'*-(4-(4-methyl-3-pyridinyl)oxyphenyl)urea;
N-(3-*tert*-Butyl-5-isoxazolyl)-*N'*-(3-(2-benzothiazolyl)oxyphenyl)urea;

N-(3-(1,1-Dimethylpropyl)-5-isoxazolyl)-*N'*-(4-(4-methylphenyl)oxyphenyl)urea;
N-(3-(1,1-Dimethylpropyl)-5-isoxazolyl)-*N'*-(3-(4-pyridinyl)thiophenyl)urea;

N-(3-(1,1-Dimethylpropyl)-5-isoxazolyl)-*N'*-(4-(4-pyridinyl)oxyphenyl)urea;

N-(3-(1,1-Dimethylpropyl)-5-isoxazolyl)-*N'*-(4-(4-pyridinyl)thiophenyl)urea;

N-(3-(1,1-Dimethylpropyl-5-isoxazolyl)-*N'*-(5-(2-(4-methoxyphenyl)oxy)pyridinyl)urea;

N-(3-(1-Methyl-1-ethylpropyl)-5-isoxazolyl)-*N'*-(4-(4-pyridinyl)oxyphenyl)urea;

N-(3-(1-Methyl-1-ethylpropyl)-5-isoxazolyl)-*N'*-(3-(4-pyridinyl)thiophenyl)urea;

N-(3-isopropyl-5-isoxazolyl)-*N'*-(3-(4-(2-methylcarbamoyl)pyridyl)-oxyphenyl) urea;

N-(3-isopropyl-5-isoxazolyl)-*N'*-(4-(4-(2-methylcarbamoyl)pyridyl)-oxyphenyl) urea;

N-(3-*tert*-butyl-5-isoxazolyl)-*N'*-(3-(4-(2-methylcarbamoyl)pyridyl)-oxyphenyl) urea;

N-(3-*tert*-butyl-5-isoxazolyl)-*N'*-(4-(4-(2-methylcarbamoyl)pyridyl)-oxyphenyl) urea;

N-(3-*tert*-butyl-5-isoxazolyl)-*N'*-(3-(4-(2-methylcarbamoyl)pyridyl)-thiophenyl) urea;

N-(3-(1,1-dimethylprop-1-yl)-5-isoxazolyl)-*N'*-(3-(4-(2-methylcarbamoyl)-pyridyl)oxyphenyl) urea;

N-(3-(1,1-dimethylprop-1-yl)-5-isoxazolyl)-*N'*-(4-(4-(2-methylcarbamoyl)-pyridyl)oxyphenyl) urea;

N-(3-*tert*-butyl-5-isoxazolyl)-*N'*-(3-chloro-4-(4-(2-methylcarbamoyl)pyridyl)-thiophenyl) urea;

and pharmaceutically acceptable salts thereof.

49. A compound of the formula



wherein R^1 is selected from the group consisting of halogen, C_3-C_{10} alkyl, C_{1-13}-heteroaryl, C_{6-14}-aryl, C_{7-24}-alkaryl, C_3-C_{10} cycloalkyl, up to per-halosubstituted C_1-C_{10} alkyl and up to per-halosubstituted C_3-C_{10} cycloalkyl, up to per-halosubstituted C_{1-13}-

heteroaryl, up to per-halosubstituted C_{6-14}-aryl , and up to per-halosubstituted C_{7-24}-alkaryl;

R^b is hydrogen or halogen and

B is an aromatic ring structure selected from the group consisting of



which is substituted or unsubstituted by halogen, up to per-halosubstitution, and

wherein n = 0-2; each X^1 is independently selected from the group consisting of X or from the group consisting of , –CN, $-OR^5$, $-NR^5R^{5'}$, C_1-C_{10} alkyl; and

X is selected from the group consisting of $-CO_2R^5$, $-C(O)NR^5R^{5'}$, $-C(O)R^5$, $-NO_2$, $-SR^5$, $-NR^5C(O)OR^{5'}$, $-NR^5C(O)R^{5'}$, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, C_7-C_{24} alkaryl, C_3-C_{13} heteroaryl, C_4-C_{23} alkheteroaryl, and substituted C_1-C_{10} alkyl, substituted C_{2-10}-alkenyl, substituted C_{1-10}-alkoxy, substituted C_3-C_{10} cycloalkyl, substituted C_6-C_{14} aryl, substituted C_7-C_{24} alkaryl, substituted C_3-C_{13} heteroaryl, substituted C_4-C_{23} alkheteroaryl, and -Y-Ar,

wherein if X is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of –CN, $-CO_2R^5$, $-C(O)R^5$, $-C(O)NR^5R^{5'}$, $-OR^5$, $-SR^5$, $-NR^5R^{5'}$, $-NO_2$, $-NR^5C(O)R^{5'}$, $-NR^5C(O)OR^{5'}$ and halogen up to per-halo substitution;

wherein R^5 and $R^{5'}$ are independently selected from H, C_1-C_{10} alkyl, C_{2-10}-alkenyl, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, C_3-C_{13} heteroaryl, C_7-C_{24} alkaryl, C_4-C_{23} alkheteroaryl, up to per-halosubstituted C_1-C_{10} alkyl, up to per-halosubstituted C_{2-10}-alkenyl; up to per-halosubstituted C_3-C_{10} cycloalkyl, up to per-halosubstituted C_6-C_{14} aryl and up to per-halosubstituted C_3-C_{13} heteroaryl,

wherein Y is - O-, -S-, -N(R^5)-, -$(CH_2)_m$-, -C(O)-, -CH(OH)-, -$(CH_2)_m$O-, -$NR^5C(O)NR^5R^{5'}$-, -$NR^5C(O)$-, -$C(O)NR^5$-, -$(CH_2)_m$S-, -$(CH_2)_m$N(R^5)-, -$O(CH_2)_m$-, -CHX^a, -CX^a_2-, -S-$(CH_2)_m$- and -N(R^5)$(CH_2)_m$-, m = 1-3, and X^a is halogen; and

Ar is a 5-10 member aromatic structure containing 0-2 members of the group consisting of nitrogen, oxygen and sulfur which is unsubstituted or substituted by halogen up to per-halosubstitution and optionally substituted by Z_{n1}, wherein n1 is 0 to 3 and each Z is independently selected from the group consisting of–CN, -CO_2R^5, -$C(O)R^5$, =O, -$C(O)NR^5R^{5'}$, -C(O)- NR^5, -NO_2, -OR^5, - SR^5, -$NR^5R^{5'}$, -$NR^5C(O)OR^{5'}$, -$NR^5C(O)R^{5'}$, -SO_2R^5, -$SO_2R^5R^{5'}$, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, C_3-C_{13} heteroaryl, C_7-C_{24} alkaryl, C_4-C_{23} alkheteroaryl, substituted C_1-C_{10} alkyl, substituted C_3-C_{10} cycloalkyl, substituted C_7-C_{24} alkaryl and substituted C_4-C_{23} alkheteroaryl; wherein if Z is a substituted group, it is substituted by the one or more substituents independently selected from the group consisting of –CN, -CO_2R^5, -$C(O)NR^5R^{5'}$, =O, -OR^5, -SR^5, -NO_2, -$NR^5R^{5'}$, -$NR^5C(O)R^{5'}$, -$NR^5C(O)OR^{5'}$, C_1-C_{10} alkyl, C_1-C_{10} alkoxyl, C_3-C_{10} cycloalkyl, , C_3-C_{13} heteroaryl, C_6-C_{14} aryl, C_4-C_{24} alkheteroaryl ,and C_7-C_{24} alkaryl,

subject to the proviso that where R^1 is t-butyl and R^b is H, B is not of the formula



50. A compound of claim 49, wherein B is



wherein

Y is selected from the group consisting of –O-, -S-, -CH_2-, -SCH_2-, -CH_2S-, -CH(OH)-, -C(O)-, -CX^a_2, -CX^aH-, -CH_2O- and -OCH_2-,

X^a is halogen,

Q is a six member aromatic structure containing 0–2 nitrogen, substituted or unsubstituted by halogen, up to per-halosubstitution;

Q^1 is a mono- or bicyclic aromatic structure of 3 to 10 carbon atoms and 0-4 members of the group consisting of N, O and S, unsubstituted or unsubstituted by halogen up to per-halosubstitution,

X, Z, n and n1 are as defined in claim 49 and s is 0 or 1.

51. A compound of claim 50, wherein

Q is phenyl or pyridinyl, substituted or unsubstituted by halogen, up to per-halosubstitution,

Q^1 is selected from the group consisting of phenyl, pyridinyl, naphthyl, pyrimidinyl, quinoline, isoquinoline, imidazole and benzothiazolyl, substituted or unsubstituted by halogen, up to per-halo, or -Y- Q^1 is phthalimidinyl substituted or unsubstituted by halogen up to per-halosubstitution, and

Z and X are independently selected from the group consisting of $–R^6$, $-OR^6$ and $–NHR^7$, wherein R^6 is hydrogen, C_1-C_{10}-alkyl or C_3-C_{10}-cycloalkyl and R^7 is selected from the group consisting of hydrogen, C_3-C_{10}-alkyl, C_3-C_6-cycloalkyl and C_6-C_{10}-aryl, wherein R^6 and R^7 can be substituted by halogen or up to per-halosubstitution.

52. A compound of the formula



wherein B is as defined in claim 49.

53. A compound of claim 50, wherein Q is phenyl, Q^1 is phenyl or pyridinyl, and Y is –O- or -S-, Z is –Cl, $-CH_3$, -OH or $-OCH_3$, n = 0, s = 0 or 1 and n1 = 0-2.

54. A compound as in claim 49 selected from the group consisting of:

N-(5-*tert*-Butyl-3-thienyl)-*N'*-(4-(3-methylphenyl)oxyphenyl)urea;
N-(5-*tert*-Butyl-3-thienyl)-*N'*-(4-(4-hydroxyphenyl)oxyphenyl)urea;
N-(5-*tert*-Butyl-3-thienyl)-*N'*-(4-(4-methoxyphenyl)oxyphenyl)urea;
N-(5-*tert*-Butyl-3-thienyl)-*N'*-(4-(4-pyridinyl)thiophenyl)urea;
and pharmaceutically acceptable salts thereof.

55. A compound of the formula



wherein R^a is C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, up to per-halosubstituted C_1-C_{10} alkyl and per-halosubstituted C_3-C_{10} cycloalkyl;

and B is an aromatic ring structure selected from the group consisting of



which is substituted or unsubstituted by halogen, up to per-halosubstitution, and wherein n = 0-2,

each X^1 is independently selected from the group consisting of X or from the group consisting of -CN, $-NO_2$, $-OR^5$ and C_1-C_{10} alkyl, and

X is selected from the group consisting of $-SR^5$, $-CO_2R^5$, $-C(O)R^5$, $-C(O)NR^5R^{5'}$, $-NR^5R^{5'}$, $-NR^5C(O)OR^{5'}$, $-NR^5C(O)R^{5'}$, -C_3-C_{10} cycloalkyl, -C_6-C_{14} aryl, -C_7-C_{24}, alkaryl, C_3-C_{13} heteroaryl, C_4-C_{23} alkheteroaryl, and substituted C_1-C_{10} alkyl, substituted C_{2-10}-alkenyl, substituted C_{1-10}-alkoxy, substituted C_3-C_{10} cycloalkyl, substituted aryl, substituted alkaryl, substituted heteroaryl, substituted C_4-C_{23} alkheteroaryl and -Y-Ar;

wherein if X is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of –CN, $-CO_2R^5$, $-C(O)R^5$, $-C(O)NR^5R^{5'}$, $-OR^5$, $-SR^5$, $-NR^5R^{5'}$, $-NO_2$, $-NR^5C(O)R^{5'}$, $-NR^5C(O)OR^{5'}$ and halogen up to per-halosubstitution;

wherein R^5 and $R^{5'}$ are independently selected from H, C_1-C_{10} alkyl, C_{2-10}-alkenyl, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, C_3-C_{13} heteroaryl, C_7-C_{24} alkaryl, C_4-C_{23} alkheteroaryl, up to per-halosubstituted C_1-C_{10} alkyl, up to per-halosubstituted C_{2-10}-alkenyl, up to per-halosubstituted C_3-C_{10} cycloalkyl, up to per-halosubstituted C_6-C_{14} aryl and up to per-halosubstituted C_3-C_{13} heteroaryl,

wherein Y is - O-, -S-, -N(R^5)-, -(CH_2)-$_m$, -C(O)-, -CH(OH)-, -(CH_2)$_m$O-, -$NR^5C(O)NR^5R^{5'}$-, -$NR^5C(O)$-, -$C(O)NR^5$-, -(CH_2)$_m$S-, -(CH_2)$_m$N(R^5)-, -O(CH_2)$_m$-, -CHX^a, -CX^a_2-, -S-(CH_2)$_m$- and -N(R^5)(CH_2)$_m$-, m = 1-3, and X^a is halogen; and

Ar is a 5-10 member aromatic structure containing 0-2 members of the group consisting of nitrogen, oxygen and sulfur which is unsubstituted or substituted by halogen up to per-halo and optionally substituted by Z_{n1}, wherein nl is 0 to 3 and each Z is independently selected from the group consisting of –CN, -CO_2R^5, -$C(O)R^5$, =O, -$C(O)NR^5R^{5'}$, -$C(O)R^5$, -NO_2, -OR^5, - SR^5, - $NR^5R^{5'}$, -$NR^5C(O)OR^{5'}$, -$NR^5C(O)R^{5'}$, -SO_2R^5, -$SO_2R^5R^{5'}$, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, C_3-C_{13} heteroaryl, C_7-C_{24} alkaryl, C_4-C_{23} alkheteroaryl, substituted C_1-C_{10} alkyl, substituted C_3-C_{10} cycloalkyl, substituted C_7-C_{24} alkaryl and substituted C_4-C_{23} alkheteroaryl; wherein if Z is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of –CN, -CO_2R^5, -$C(O)NR^5R^{5'}$, =O, -OR^5, -SR^5, -NO_2, -$NR^5R^{5'}$, -$NR^5C(O)R^{5'}$ and -$NR^5C(O)OR^{5'}$, C_1-C_{10} alkyl, C_1-C_{10} alkoxyl, C_3-C_{10} cycloalkyl, , C_3-C_{13} heteroaryl, C_6-C_{14} aryl, C_4-C_{24} alkheteroaryl , and C_7-C_{24} alkaryl.

56. A compound as in claim 55, wherein B is



wherein

Y is selected from the group consisting of –O-, -S-, -CH_2-, -SCH_2-, -CH_2S-, -CH(OH)-, -C(O)-, -CX^a_2, -CX^aH-, -CH_2O-, -OCH_2-,

X^a is halogen,

Q is a six member aromatic structure containing 0–2 nitrogen, substituted or unsubstituted by halogen, up to per-halosubstitution;

Q^1 is a mono- or bicyclic aromatic structure of 3 to 10 carbon atoms and 0-4 members of the group consisting of N, O and S, unsubstituted or unsubstituted by halogen up to per-halosubstitution,

X, Z, n and n1 are as defined in claim 55, and s is 0 or 1.

57. A compound as in claim 56, wherein

Q is phenyl or pyridinyl, substituted or unsubstituted by halogen, up to per-halosubstitution,

Q^1 is selected from the group consisting of phenyl, pyridinyl, naphthyl, pyrimidinyl, quinoline, isoquinoline, imidazole and benzothiazolyl, substituted or unsubstituted by halogen, up to per-halo, or -Y-Q^1 is phthalimidinyl substituted or unsubstituted by halogen up to per-halosubstitution, and

Z and X are independently selected from the group consisting of $-R^6$, $-OR^6$ and $-NHR^7$, wherein R^6 is hydrogen, C_1-C_{10}-alkyl or C_3-C_{10}-cycloalkyl and R^7 is selected from the group consisting of hydrogen, C_3-C_{10}-alkyl, C_3-C_6-cycloalkyl and C_6-C_{10}-aryl, wherein R^6 and R^7 can be substituted by halogen or up to per-halosubstitution.

58. A compound as in claim 55, wherein B is of the formula



wherein Q is phenyl, Q^1 is phenyl or pyridinyl, Y is –O- or –S-, s = 1, n = 0 and n1 = 0.

59. A compound as in claim 55, of the formula



wherein B is as defined in claim 55.

60. A compound as in claim 55 selected from the group consisting of:

N-(5-*tert*-Butyl-2-(1-thia-3,4-diazolyl))-*N'*-(3-(4-pyridinyl)thiophenyl)urea;

N-(5-*tert*-Butyl-2-(1-thia-3,4-diazolyl))-*N'*-(4-(4-pyridinyl)oxyphenyl)urea;

N-(5-*tert*-butyl-2-(1-thia-3,4-diazolyl))-*N'*-(3-(4-(2-methylcarbamoyl)pyridyl)-oxyphenyl) urea;

N-(5-*tert*-butyl-2-(1-thia-3,4-diazolyl))-*N'*-(4-(4-(2-methylcarbamoyl)pyridyl)-oxyphenyl) urea;

N-(5-*tert*-butyl-2-(1-thia-3,4-diazolyl))-*N'*-(3-chloro-4-(4-(2-methylcarbamoyl)pyridyl)-oxyphenyl) urea;

N-(5-*tert*-butyl-2-(1-thia-3,4-diazolyl))-*N'*-(2-chloro-4-(4-(2-methylcarbamoyl)pyridyl)-oxyphenyl) urea;

N-(5-*tert*-butyl-2-(1-thia-3,4-diazolyl))-*N'*-(3-(4-pyridyl)thiophenyl) urea;

N-(5-*tert*-butyl-2-(1-thia-3,4-diazolyl))-*N'*-(2-methyl-4-(4-(2-methylcarbamoyl)pyridyl)oxyphenyl) urea;

N-(5-(1,1-dimethylprop-1-yl)-2-(1-thia-3,4-diazolyl))-*N'*-(4-(3-carbamoylphenyl)oxyphenyl) urea;

and pharmaceutically acceptable salts thereof.

61. A compound of one of the formulae



R^1 is selected from the group consisting of halogen, C_3-C_{10} alkyl, C_{1-13}-heteroaryl, C_{6-14}-aryl, C_{7-24}-alkaryl, C_3-C_{10} cycloalkyl, up to per-halosubstituted C_1-C_{10} alkyl, up to per-halosubstituted C_3-C_{10} cycloalkyl, up to per-halosubstituted C_{1-13}-heteroaryl, up to per-halosubstituted C_{6-14}-aryl , and up to per-halosubstituted C_{7-24}-alkaryl;

B is an aromatic ring structure selected from the group consisting of





which is substituted or unsubstituted by halogen, up to per-halosubstitution, and wherein n = 0-2;

each X^1 is independently selected from the group consisting of X or from the group consisting of –CN, $-OR^5$, $-NR^5R^{5'}$, C_1-C_{10} alkyl; and

X is selected from the group consisting of $-CO_2R^5$, $-C(O)NR^5R^{5'}$, $-C(O)R^5$, =O, $-NO_2$, $-SR^5$, $-NR^5C(O)OR^{5'}$, $-NR^5C(O)R^{5'}$, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, C_7-C_{24} alkaryl, C_3-C_{13} heteroaryl, C_4-C_{23} alkheteroaryl, and substituted C_1-C_{10} alkyl, substituted C_{2-10}-alkenyl, substituted C_{1-10}-alkoxy, substituted C_3-C_{10} cycloalkyl, substituted C_6-C_{14} aryl, substituted C_7-C_{24} alkaryl, substituted C_3-C_{13} heteroaryl, substituted C_4-C_{23} alkheteroaryl, and -Y-Ar,

wherein if X is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of –CN, $-CO_2R^5$, $-C(O)R^5$, $-C(O)NR^5R^{5'}$, $-OR^5$, $-SR^5$, $-NR^5R^{5'}$, $-NO_2$, $-NR^5C(O)R^{5'}$, $-NR^5C(O)OR^{5'}$ and halogen up to per-halo substitution;

wherein R^5 and $R^{5'}$ are independently selected from H, C_1-C_{10} alkyl, C_{2-10}-alkenyl, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, C_3-C_{13} heteroaryl, C_7-C_{24} alkaryl, C_4-C_{23} alkheteroaryl, up to per-halosubstituted C_1-C_{10} alkyl, up to per-halosubstituted C_{2-10}-alkenyl, up to per-halosubstituted C_3-C_{10} cycloalkyl, up to per-halosubstituted C_6-C_{14} aryl and up to per-halosubstituted C_3-C_{13} heteroaryl,

wherein Y is - O-, -S-, $-N(R^5)$-, $-(CH_2)_m$-, -C(O)-, -CH(OH)-, $-(CH_2)_mO$-, $-NR^5C(O)NR^5R^{5'}$-, $-NR^5C(O)$-, $-C(O)NR^5$-, $-(CH_2)_mS$-, $-(CH_2)_mN(R^5)$-, $-O(CH_2)_m$-, $-CHX^a$, $-CX^a_2$-, $-S-(CH_2)_m$- and $-N(R^5)(CH_2)_m$-,

m = 1-3, and X^a is halogen; and

Ar is a 5-10 member aromatic structure containing 0-2 members of the group consisting of nitrogen, oxygen and sulfur which is unsubstituted or substituted by halogen up to per-halosubstitution and optionally substituted by Z_{n1}, wherein n1 is 0 to 3 and each Z is independently selected from the group consisting of –CN, $-CO_2R^5$, =O, $-C(O)R^5$, $-C(O)NR^5R^{5'}$, -C(O)- NR^5, $-NO_2$, $-OR^5$, - SR^5, - $NR^5R^{5'}$, $-NR^5C(O)OR^{5'}$, $-NR^5C(O)R^{5'}$, $-SO_2R^5$, $-SO_2R^5R^{5'}$, C_1-C_{10} alkyl, C_1-C_{10} alkoxy, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, C_3-C_{13} heteroaryl, C_7-C_{24} alkaryl, C_4-C_{23} alkheteroaryl, substituted C_1-C_{10} alkyl, substituted C_3-C_{10} cycloalkyl, substituted C_7-C_{24} alkaryl and substituted C_4-C_{23} alkheteroaryl; wherein if Z is a substituted group, it is substituted by the one or more substituents independently selected from the group consisting of –CN, $-CO_2R^5$, $-C(O)NR^5R^{5'}$, =O, $-OR^5$, $-SR^5$, $-NO_2$, $-NR^5R^{5'}$, $-NR^5C(O)R^{5'}$, $-NR^5C(O)OR^{5'}$, C_1-C_{10} alkyl, C_1-C_{10} alkoxyl, C_3-C_{10} cycloalkyl, , C_3-C_{13} heteroaryl, C_6-C_{14} aryl, C_4-C_{24} alkheteroaryl , and C_7-C_{24} alkaryl.

62. A compound of one of the formulae



wherein B is as defined in claim 61.

63. A compound of claim 61, wherein B is



wherein

Y is selected from the group consisting of –O-, -S-, $-CH_2$-, $-SCH_2$-, $-CH_2S$-, -CH(OH)-, -C(O)-, $-CX^a_2$, $-CX^aH$-, $-CH_2O$- and $-OCH_2$-,

X^a is halogen,

Q is a six member aromatic structure containing 0–2 nitrogen, substituted or unsubstituted by halogen, up to per-halosubstitution;

Q^1 is a mono- or bicyclic aromatic structure of 3 to 10 carbon atoms and 0-4 members of the group consisting of N, O and S, unsubstituted or unsubstituted by halogen up to per-halosubstitution,

X, Z, n and n1 are as defined in claim 61 and s is 0 or 1.

64. A compound of claim 63, wherein

Q is phenyl or pyridinyl, substituted or unsubstituted by halogen, up to per-halosubstitution,

Q^1 is selected from the group consisting of phenyl, pyridinyl, naphthyl, pyrimidinyl, quinoline, isoquinoline, imidazole and benzothiazolyl, substituted or unsubstituted by halogen, up to per-halo, or -Y- Q^1 is phthalimidinyl substituted or unsubstituted by halogen up to per-halosubstitution, and

Z and X are independently selected from the group consisting of $-R^6$, $-OR^6$ and $-NHR^7$, wherein R^6 is hydrogen, C_1-C_{10}-alkyl or C_3-C_{10}-cycloalkyl and R^7 is selected from the group consisting of hydrogen, C_3-C_{10}-alkyl, C_3-C_6-cycloalkyl and C_6-C_{10}-aryl, wherein R^6 and R^7 can be substituted by halogen or up to per-halosubstitution.

65. A compound of claim 61, wherein B is up to per-halosubstituted phenyl, up to perhalosubstituted pyridinyl, or of the formula



wherein Q is phenyl, Q^1 is phenyl or pyridinyl, and Y is –O- or -S-, Z is –Cl, $-CH_3$, -OH or OCH_3, n = 0, s = 0 or 1 and n1 = 0-2.

66. A compound of the formula



wherein R^1 is selected from the group consisting of halogen, C_3-C_{10} alkyl, C_3-C_{10} cycloalkyl, C_{1-13}-heteroaryl, C_{6-14}-aryl, C_{7-24}-alkaryl, up to per-halosubstituted C_1-C_{10} alkyl and up to per-halosubstituted C_3-C_{10} cycloalkyl up to per-halosubstituted C_{1-13}-heteroaryl, up to per-halosubstituted C_{6-14}-aryl, up to per-halosubstituted C_{7-24}-alkaryl; R^b is hydrogen or halogen and

wherein B is up to a tricyclic aromatic ring structure selected from the group consisting of



which is substituted or unsubstituted by halogen, up to per-halosubstitution, and wherein

n = 0-3 and

each X is independently selected from the group consisting of –CN, $-CO_2R^5$, $-C(O)NR^5R^{5'}$, $-C(O)R^5$, $-NO_2$, $-OR^5$, $-SR^5$, $-NR^5R^{5'}$, $-NR^5C(O)OR^{5'}$, $-NR^5C(O)R^{5'}$, C_1-C_{10} alkyl, C_{2-10}-alkenyl, C_{1-10}-alkoxy, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, C_7-C_{24} alkaryl, C_3-C_{13} heteroaryl, C_4-C_{23} alkheteroaryl, and substituted C_1-C_{10} alkyl, substituted C_{2-10}-alkenyl, substituted C_{1-10}-alkoxy, substituted C_3-C_{10} cycloalkyl, substituted C_4-C_{23} alkheteroaryl and -Y-Ar;

wherein if X is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of –CN, $-CO_2R^5$, $-C(O)R^5$, $-C(O)NR^5R^{5'}$, $-OR^5$, $-SR^5$, $-NR^5R^{5'}$, $-NO_2$, $-NR^5C(O)R^{5'}$, $-NR^5C(O)OR^{5'}$ and halogen up to per-halosubstitution;

wherein R^5 and $R^{5'}$ are independently selected from H, C_1-C_{10} alkyl, C_{2-10}-alkenyl, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, C_3-C_{13} heteroaryl, C_7-C_{24} alkaryl, C_4-C_{23} alkheteroaryl, up to per-halosubstituted C_1-C_{10} alkyl, up to per-halosubstituted C_{2-10}-alkenyl, up to per-halosubstituted C_3-C_{10} cycloalkyl, up to per-halosubstituted C_6-C_{14} aryl and up to per-halosubstituted C_3-C_{13} heteroaryl,

wherein Y is - O-, -S-, -N(R^5)-, -(CH_2)-$_m$, -C(O)-, -CH(OH)-, -$(CH_2)_m$O-, -$NR^5C(O)NR^5R^{5'}$-, -$NR^5C(O)$-, -$C(O)NR^5$-, -$(CH_2)_mS$-, -$(CH_2)_mN(R^5)$-, -$O(CH_2)_m$-, -CHX^a, -CX^a_2-, -S-$(CH_2)_m$- and -N(R^5)$(CH_2)_m$-,

m = 1-3, and X^a is halogen; and

Ar is a 5-10 member aromatic structure containing 0-2 members of the group consisting of nitrogen, oxygen and sulfur which is unsubstituted or substituted by halogen up to per-halo and optionally substituted by Z_{n1}, wherein nl is 0 to 3 and each Z is independently selected from the group consisting of –CN, -CO_2R^5, -C(O)R^5, =O, -$C(O)NR^5R^{5'}$, -C(O)R^5, -NO_2, -OR^5, - SR^5, - $NR^5R^{5'}$,-$NR^5C(O)OR^{5'}$, -$NR^5C(O)R^{5'}$, -SO_2R^5, -SO_2 $R^5R^{5'}$, C_1-C_{10} alkyl, C_3-C_{10} cycloalkyl, C_6-C_{14} aryl, C_3-C_{13} heteroaryl, C_7-C_{24} alkaryl, C_4-C_{23} alkheteroaryl, substituted C_1-C_{10} alkyl, substituted C_3-C_{10} cycloalkyl, substituted C_7-C_{24} alkaryl and substituted C_4-C_{23} alkheteroaryl; wherein if Z is a substituted group, it is substituted by one or more substituents independently selected from the group consisting of –CN, -CO_2R^5, -C(O)$NR^5R^{5'}$, =O, -OR^5, -SR^5, -NO_2, -$NR^5R^{5'}$, -$NR^5C(O)R^{5'}$, -$NR^5C(O)OR^{5'}$, C_1-C_{10} alkyl, C_1-C_{10} alkoxyl, C_3-C_{10} cycloalkyl, , C_3-C_{13} heteroaryl, C_6-C_{14} aryl, C_4-C_{24} alkheteroaryl ,and C_7-C_{24} alkaryl.

67. A compound of claim 66, wherein B is



wherein

Y is selected from the group consisting of –O-, -S-, -CH_2-, -SCH_2-, -CH_2S-, -CH(OH)-, -C(O)-, -CX^a_2, -CX^aH-, -CH_2O- and -OCH_2-,

X^a is halogen,

Q is a six member aromatic structure containing 0–2 nitrogen; substituted or unsubstituted by halogen, up to per-halosubstitution;

Q^1 is a mono- or bicyclic aromatic structure of 3 to 10 carbon atoms and 0-4 members of the group consisting of N, O and S, unsubstituted or unsubstituted by halogen up to per-halosubstitution,

X, Z, n and n1 are as defined in claim 66 and s is 0 or 1.

68. A compound of claim 67, wherein

Q is phenyl or pyridinyl, substituted or unsubstituted by halogen, up to per-halosubstitution,

Q^1 is selected from the group consisting of phenyl, pyridinyl, naphthyl, pyrimidinyl, quinoline, isoquinoline, imidazole and benzothiazolyl, substituted or unsubstituted by halogen, up to per-halo, or -Y-Q^1 is phthalimidinyl substituted or unsubstituted by halogen up to per-halosubstitution, and

Z and X are independently selected from the group consisting of $-R^6$, $-OR^6$ and $-NHR^7$, wherein R^6 is hydrogen, C_1-C_{10}-alkyl or C_3-C_{10}-cycloalkyl and R^7 is selected from the group consisting of hydrogen, C_3-C_{10}-alkyl, C_3-C_6-cycloalkyl and C_6-C_{10}-aryl, wherein R^6 and R^7 can be substituted by halogen or up to per-halosubstitution.

69. A compound of the formula



wherein B is as defined in claim 66.

70. A compound as in claim 66, wherein B is of the formula



Q is phenyl, Q^1 is phenyl or pyridinyl, and Y is –O- or -S-, Z is –Cl or $-OCH_3$, n = 0, s = 0 and n1 = 0-2.

71. A pharmaceutical composition comprising a compound according to claim 31 and a physiologically acceptable carrier.

72. A pharmaceutical composition comprising a compound according to claim 37 and a physiologically acceptable carrier.

73. A pharmaceutical composition comprising a compound according to claim 43 and a physiologically acceptable carrier.

74. A pharmaceutical composition comprising a compound according to claim 49 and a physiologically acceptable carrier.

75. A pharmaceutical composition comprising a compound according to claim 55 and a physiologically acceptable carrier.

76. A pharmaceutical composition comprising a compound according to claim 61 and a physiologically acceptable carrier.

77. A pharmaceutical composition comprising a compound according to claim 66 and a physiologically acceptable carrier.

add
a137